Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous pCAR-19B CAR-T cells in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia
CTR20241718Phase 2Active
- Sponsor
- Chongqing Precision Biotech
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of priscabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Started Jul 2024; status: active.
02
Drugs
priscabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20241718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241718.